About 300 reports

Filgrastim Sales, Price Analysis, & Sales Forecast - 2017 ##.

  • Biological Therapy
  • Biotechnology
  • Filgrastim
  • World
  • Demand
  • filgrastim
  • filgrastim

“Oncology drugs report - Neupogen and Neulasta - filgrastim franchise - 1991-2015 analysis; 2016-2021 expectations” is a comprehensive report on Neupogen and Neulasta, two market leading drugs (by 2015 sales) used in the treatment of chemotherapy-induced febrile neutropenia. These drugs, both belonging to biotech giant Amgen, fall under...

  • Biotechnology
  • United States
  • Amgen Inc.
  • Kyowa Hakko Kirin Co., Ltd.
  • Neupogen group
  • FILGRASTIM - DRUG PROFILE
  • FILGRASTIM - DRUG PROFILE

Chemotherapy Induced Neutropenia - Pipeline Review, H2 2017 Summary Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Chemotherapy Induced Neutropenia - Pipeline Review, H2 2017, provides an overview of the Chemotherapy Induced Neutropenia (Toxicology) pipeline landscape. Chemotherapy-induced...

  • Biotechnology
  • Chemotherapy
  • United States
  • World
  • Product Initiative
  • FILGRASTIM - DRUG PROFILE
  • FILGRASTIM - DRUG PROFILE

Neutropenia - Pipeline Review, H2 2017 Summary Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Neutropenia - Pipeline Review, H2 2017, provides an overview of the Neutropenia (Hematological Disorders) pipeline landscape. Neutropenia is an abnormally low count of neutrophils,...

  • Biosimilar
  • Biotechnology
  • United States
  • Product Initiative
  • Coherus BioSciences, Inc.
  • FILGRASTIM
  • Japan

The global biosimilars market projected to grow at a CAGR of 31.7% during the forecast period. The biosimilars market is expected to reach USD 23.63 billion by 2023 from USD 5.95 billion in 2018, at a CAGR of 31.7%. Factors driving the growth of this market include increasing demand for biosimilar drugs due to their cost-effectiveness,...

  • Biopharmaceutical
  • Biosimilar
  • Biotechnology
  • Generic Drug
  • Pharmaceutical
  • FILGRASTIM - DRUG PROFILE
  • FILGRASTIM - DRUG PROFILE

Febrile Neutropenia - Pipeline Review, H2 2016 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Febrile Neutropenia - Pipeline Review, H2 2016, provides an overview of the Febrile Neutropenia (Hematological Disorders) pipeline landscape. Febrile neutropenia can develop...

  • Biotechnology
  • United States
  • World
  • Product Initiative
  • Coherus BioSciences, Inc.
  • filgrastim - Drug Profile
  • Biocon Limited - Early Stage Pipeline Products

Biocon Limited - Product Pipeline Review - 2016 Summary Global Markets Direct’s, ‘Biocon Limited - Product Pipeline Review - 2016’, provides an overview of the Biocon Limited’s pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by Biocon...

  • Biotechnology
  • Insulin
  • World
  • Product Initiative
  • Biocon Limited
  • FILGRASTIM
  • FILGRASTIM - DRUG PROFILE

Chemotherapy Induced Neutropenia - Pipeline Review, H1 2018 Summary Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Chemotherapy Induced Neutropenia - Pipeline Review, H1 2018, provides an overview of the Chemotherapy Induced Neutropenia (Toxicology) pipeline landscape. Chemotherapy-induced...

  • Biotech
  • Biotechnology
  • Chemotherapy
  • Pharmaceutical
  • Therapy

ZYDUS CADILA Chapter ## Appendix: Abbreviations List of Tables Summary Table : Global Market for Biosimilars, by Type, Through 2022 Table ## : List of Biosimilars Produced in E.

  • Biopharmaceutical
  • Biosimilar
  • Biotechnology
  • Generic Drug
  • World
  • ZARXIO: PARAMETERS TO TEST SIMILARITY
  • ZARXIO: OVERVIEW

Global Biosimilar Pipeline and Market Prospects: Addressing Production Complexities Through Risk Management and Quality by Design Summary Government support for biosimilars is increasing in key geographical markets, given the cost saving opportunities that these products represent for national healthcare budgets. A...

  • Biopharmaceutical
  • Biosimilar
  • Biotechnology
  • Generic Drug
  • Monoclonal Antibody
  • undisclosed chemotherapy, topotecan hydrochloride, melphalan, filgrastim, busulfan and autologous hematopoietic stem cells alone or in combination have the highest number of nonseminomatous testicular cancer ongoing clinical trials.

Nonseminomatous Testicular Cancer Global Clinical Trials Review, H1, 2018 Summary GlobalData’s clinical trial report, “Nonseminomatous Testicular Cancer Global Clinical Trials Review, H1, 2018" provides an overview of Nonseminomatous Testicular Cancer clinical trials scenario.This report provides...

  • Biotechnology
  • Chemotherapy
  • Therapy
  • World
  • Product Initiative
  • Strength 1 Low; 5 High
  • First biosimilar approved in Americas

About Neutropenia Treatment Neutropenia is an abnormal condition, characterized by critically low levels of circulating neutrophils, a type of WBC found in the blood. These cells make up for the majority of circulating lymphocytes and help defend the body against infections by bacteria, viruses, and other pathogenic organisms....

  • Biotechnology
  • Therapy
  • Amgen Inc.
  • Novartis AG
  • Teva Pharmaceutical Industries Ltd.
  • Cancer
  • PFIZER INC. - MAJOR BIOSIMILARS APPROVED FOR MARKETING

The biosimilars are poised to capture an unprecedented position in the biopharmaceutical industry driven by an increased extent of adoption and growing investment and deal making activity globally. The global biosimilars market is predicted to cross US$ 25 Billion mark by 2020. With the continuous increasing demand for biologics,...

  • Biopharmaceutical
  • Biosimilar
  • Biotechnology
  • Generic Drug
  • Pharmaceutical
  • Filgrastim: Biosimilar Products in South Korea
  • Filgrastim: Biosimilar Products in China & Taiwan - 1/2

Filgrastim & Pegfilgrastim Biosimilars & Biosuperiors 2015 – a G-CSF & GM-CSF Competitor Analysis The Competitive Intelligence report Filgrastim & Pegfilgrastim Biosimilars & Biosuperiors 2015 – a G-CSF & GM-CSF Competitor Analysis describes product portfolios and...

  • Biotechnology
  • Filgrastim
  • G-CSF
  • United States
  • Amgen Inc.

Global Biosimilars and Follow-On Biologics Market 2017-2027 ##.

  • Biosimilar
  • Biotechnology
  • World
  • Market Shares
  • Market Size
  • Biosimilars approved by PMDA in Japan
  • Assumptions

About Biosimilars Biosimilars are defined as the follow-on versions of original biological medicines. These are separately developed after the patent protecting the original product has expired. Biosimilars are intended to have the same MOA as original biological drugs and are designed to treat the same diseases as the innovator’s product....

  • Biotechnology
  • Biocon Limited
  • Hospira, Inc.
  • Sandoz Inc.
  • Teva Pharmaceuticals Ltd.
  • 5.2.2 APPROVED BIOSIMILARS IN THE US AS OF DECEMBER 2017
  • 9.1 APOTEX INC.

The company has received approval for tbo-filgrastim (XM## filgrastim).

  • Biotechnology
  • Biocon Limited
  • Mylan Inc.
  • Pfizer Inc.
  • Sandoz Inc.
  • FILGRASTIM - DRUG PROFILE
  • FILGRASTIM - DRUG PROFILE

Neutropenia - Pipeline Review, H1 2018 Summary Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Neutropenia - Pipeline Review, H1 2018, provides an overview of the Neutropenia (Hematological Disorders) pipeline landscape. Neutropenia is an abnormally low...

  • Biotechnology
  • Pharmaceutical
  • Therapy
  • United States
  • Product Initiative
  • FILGRASTIM - DRUG PROFILE
  • Febrile Neutropenia - Recent Pipeline Updates

Febrile Neutropenia - Pipeline Review, H1 2016 Summary Global Markets Direct’s, ‘Febrile Neutropenia - Pipeline Review, H1 2016’, provides an overview of the Febrile Neutropenia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Febrile Neutropenia, complete...

  • Biosimilar
  • Biotechnology
  • Research And Development
  • United States
  • Company Operations

Charting the Global Biosimialr pipeline ##.

  • Biosimilar
  • Biotechnology
  • Therapy

Global Biosimilar Drugs Market Analysis 2016 - Forecast to 2022 ## Introduction ##. ## Scope of the Report ##. ## Report Description ##. ## Research Methodology ##. ## Research Sources ##. ##. ## Primary Research Sources ##. ##. ## Secondary Research Sources ##. ##. ## Assumptions ##. ## List of Abbreviations ## Executiv

  • Biotechnology
  • APAC
  • North America
  • World
  • Market Size
  • filgrastim alone or in combination has the highest number of neutropenia ongoing clinical trials.
  • Clinical Trial profile. 13 Trial Title

Neutropenia Global Clinical Trials Review, H2, 2016 Summary GlobalData's clinical trial report, “Neutropenia Global Clinical Trials Review, H2, 2016" provides an overview of Neutropenia clinical trials scenario. This report provides top line data relating to the clinical trials on Neutropenia. Report includes an overview...

  • Biotechnology
  • Blood Disease
  • Therapy
  • World
  • Product Initiative
  • Target
  • Clinical Trial profile. 278 Trial Title

Leukocyte Disorders (White Blood Cell Disorders) Global Clinical Trials Review, H2, 2017 Summary GlobalData’s clinical trial report, “Leukocyte Disorders (White Blood Cell Disorders) Global Clinical Trials Review, H2, 2017" provides an overview of Leukocyte Disorders (White Blood Cell Disorders)...

  • Biotechnology
  • Blood Disease
  • Blood Supply
  • Clinical Trial
  • Therapy
  • Biologics/biosimilars market in Japan
  • Hospira

About Oncology Biosimilars Cancer represents a huge burden on healthcare systems worldwide due to the high cost of treatment therapeutics. The patent expiry of many cancer therapeutics enables the entry of biosimilars into the market. Biosimilars are being incorporated into oncology treatment practices in the supportive care setting....

  • Biotechnology
  • Biocon Limited
  • Celltrion, Inc.
  • Hospira, Inc.
  • Sandoz Inc.

You can easily book an appointment with one online.

  • Biotechnology
  • World
  • Forecast
  • Merck & Co., Inc.
  • Sanofi S.A.
  • Official Title
  • Official Title

Neutropenia Global Clinical Trials Review, H1, 2018 Summary GlobalData’s clinical trial report, “Neutropenia Global Clinical Trials Review, H1, 2018" provides an overview of Neutropenia clinical trials scenario.This report provides top line data relating to the clinical trials on Neutropenia. Report...

  • Biotechnology
  • Blood Disease
  • Clinical Trial
  • Therapy
  • World
  • Target
  • Clinical Trial profile. 37 Trial Title

Chemotherapy Induced Neutropenia Global Clinical Trials Review, H1, 2017 Summary GlobalData’s clinical trial report, “Chemotherapy Induced Neutropenia Global Clinical Trials Review, H1, 2017" provides an overview of Chemotherapy Induced Neutropenia clinical trials scenario. This report provides top line data relating...

  • Biotechnology
  • Chemotherapy
  • Therapy
  • World
  • Product Initiative
  • US Approved Biosimilars
  • 2.3 Overview of Biosimilars

Scope of the Report The report entitled “Global Biosimilar Market: Size, Trends & Forecasts (2016-2020)”, provides an analysis of global biosimilar market in terms of value. The report also provides a brief analysis of the global biologics market by value and market share by products. Furthermore, the report also assesses...

  • Biotechnology
  • Amgen Inc.
  • Celltrion, Inc.
  • Pfizer Inc.
  • Sandoz Inc.
  • Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) - Dormant Products

Similarly, the universities portfolio in Phase I and Preclinical stages comprises ## and ## molecules, respectively.

  • Biotechnology
  • Prostate Cancer
  • World
  • Product Initiative
  • OncBioMune Pharmaceuticals, Inc.